Chediak-Higashi syndrome: Lessons from a single-centre case series

Area of Science:

• Immunology
• Genetics
• Pediatrics

Background:

• Chediak-Higashi syndrome (CHS) is a rare, autosomal recessive disorder.
• Characterized by recurrent infections, oculocutaneous albinism, and progressive neurologic dysfunction.
• Associated with a significant risk of mortality.

Purpose of the Study:

• To describe the clinical characteristics and outcomes of patients with CHS.
• To evaluate the impact of diagnostic and therapeutic advancements over time.
• To highlight the importance of early disease identification.

Main Methods:

• Retrospective analysis of 14 CHS patients diagnosed between 1986 and 2018.
• Data collection included demographics, clinical findings, laboratory results, and treatment outcomes.
• Evaluation of disease progression, complications like hemophagocytic lymphohistiocytosis (HLH), and survival.

Main Results:

• Recurrent infections and oculocutaneous albinism were common in CHS patients.
• Seven patients developed hemophagocytic lymphohistiocytosis (HLH), a severe complication.
• Survival rates improved over the study period, with bone marrow transplantation (BMT) showing positive outcomes.

Conclusions:

• Prognosis for CHS patients has improved over the last 30 years.
• Standardized management protocols for HLH have enhanced survival.
• Early CHS identification and BMT are crucial for altering the disease's course.